0001144204-17-063223.txt : 20171211
0001144204-17-063223.hdr.sgml : 20171211
20171211210135
ACCESSION NUMBER: 0001144204-17-063223
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171127
FILED AS OF DATE: 20171211
DATE AS OF CHANGE: 20171211
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Weyer Christian
CENTRAL INDEX KEY: 0001493811
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35668
FILM NUMBER: 171250735
MAIL ADDRESS:
STREET 1: 9360 TOWNE CENTRE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INTERCEPT PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001270073
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 223868459
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 450 W. 15TH STREET
STREET 2: SUITE 505
CITY: NEW YORK
STATE: NY
ZIP: 10011
BUSINESS PHONE: 646-747-1000
MAIL ADDRESS:
STREET 1: 450 W. 15TH STREET
STREET 2: SUITE 505
CITY: New York
STATE: NY
ZIP: 10011
4
1
tv480792_4.xml
OWNERSHIP DOCUMENT
X0306
4
2017-11-27
0
0001270073
INTERCEPT PHARMACEUTICALS INC
ICPT
0001493811
Weyer Christian
C/O INTERCEPT PHARMACEUTICALS, INC.
10 HUDSON YARDS, FLOOR 37
NEW YORK
NY
10001
0
1
0
0
EVP Research and Development
Common Stock
2017-11-27
4
A
0
16500
0
A
16500
D
Option to Purchase Common Stock
59.12
2017-11-27
4
A
0
25000
0
A
2027-11-27
Common Stock
25000
25000
D
25% of the shares of restricted stock will vest on November 27, 2018, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The remaining shares of restricted stock will vest pro rata on every subsequent three-month anniversary of the initial vesting date through November 27, 2021 (representing the vesting on each such vesting date of 6.25% of the shares of restricted stock), subject to the terms and conditions of the award and the 2012 Plan.
25% of the shares of common stock underlying this option will vest on November 27, 2018, subject to the terms and conditions of the award and the 2012 Plan. The remainder of the shares of common stock underlying this option will vest pro rata on a monthly basis after the initial vesting date through November 27, 2021 (representing the vesting on each such vesting date of approximately 2.0833% of the shares of common stock initially underlying this option), subject to the terms and conditions of the award and the 2012 Plan.
/s/ Mark Pruzanski, as attorney-in-fact
2017-12-11